Ensuring continued progress for development of COVID-19 therapeutics in children.

Pediatr Res · 2021 · PMC7891471 · PMID 33603214

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

In addition, although there may be significant experience in using these existing therapies for chronic immune-mediated diseases in children, there may be little or no experience in using them in patients who would be at the greatest risk from COVID-19 such as infants, those who are otherwise immunocompromised, and those with pre-existing complex medical conditions.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.